SCIO-469 + bortezomib

SCIO-469 (talmapimod) is an orally active, selective inhibitor of p38α mitogen-activated protein kinase (MAPK), which blocks the synthesis of proinflammatory cytokines such as IL-1β, PGE2, VEGF, MIP-1α and TNFα. This inhibition reduces multiple myeloma tumor growth and survival and can help overcome drug resistance[2][7]. Bortezomib is a small molecule proteasome inhibitor that blocks the 26S proteasome in cells, leading to accumulation of proteins within cancer cells and subsequent cell death. It is approved for use in multiple myeloma and mantle cell lymphoma[1]. The combination of SCIO-469 with bortezomib has been studied in relapsed or refractory multiple myeloma patients; clinical trials showed that this combination was well tolerated with some evidence of efficacy[2][5].

Brand names

Boruzu

Other names

talmapimod